{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:03:23Z","timestamp":1787623403087,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011789","name":"Jilin Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["20230508102RC"],"award-info":[{"award-number":["20230508102RC"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004739","name":"Chinese Academy of Sciences Youth Innovation Promotion Association","doi-asserted-by":"publisher","award":["2022224"],"award-info":[{"award-number":["2022224"]}],"id":[{"id":"10.13039\/501100004739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52073279"],"award-info":[{"award-number":["52073279"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52273157"],"award-info":[{"award-number":["52273157"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003807","name":"People's Government of Jilin Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004032","name":"Jilin University","doi-asserted-by":"publisher","award":["20230454"],"award-info":[{"award-number":["20230454"]}],"id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2023-03-36"],"award-info":[{"award-number":["320.6750.2023-03-36"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.actbio.2024.09.033","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T12:40:56Z","timestamp":1727354456000},"page":"532-544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Dual immunostimulatory CD73 antibody-polymeric cytotoxic drug complex for triple negative breast cancer therapy"],"prefix":"10.1016","volume":"189","author":[{"given":"Xiao","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-1060","authenticated-orcid":false,"given":"Na","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.actbio.2024.09.033_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.actbio.2024.09.033_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.actbio.2024.09.033_bib0003","first-page":"95","article-title":"Triple negative breast cancer: pitfalls and progress, npj","volume":"8","author":"Zagami","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.actbio.2024.09.033_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2022.108253","article-title":"Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options","volume":"237","author":"So","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.actbio.2024.09.033_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer \u2014 Expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.actbio.2024.09.033_bib0006","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.actbio.2024.09.033_bib0007","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","article-title":"Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial","volume":"35","author":"Spring","year":"2024","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.actbio.2024.09.033_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.actbio.2024.09.033_bib0009","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/oncolo\/oyad246","article-title":"Predicting response to antibody drug conjugates: a focus on antigens' targetability","volume":"28","author":"Ascione","year":"2023","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.actbio.2024.09.033_bib0010","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.actbio.2024.09.033_bib0011","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11095-023-03649-z","article-title":"Antibody-drug conjugate overview: a state-of-the-art manufacturing process and control strategy","volume":"41","author":"Li","year":"2024","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.actbio.2024.09.033_bib0012","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody-drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.actbio.2024.09.033_bib0013","first-page":"165","article-title":"Antibody\u2013drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.actbio.2024.09.033_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102227","article-title":"Turning tumors from cold to inflamed to improve immunotherapy response","volume":"101","author":"Gerard","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.actbio.2024.09.033_bib0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/2159-8290.CD-22-0475","article-title":"The great immune escape: understanding the divergent immune response in breast cancer subtypes","volume":"13","author":"Onkar","year":"2023","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.actbio.2024.09.033_bib0016","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.actbio.2024.09.033_bib0017","doi-asserted-by":"crossref","first-page":"eadd6626","DOI":"10.1126\/sciadv.add6626","article-title":"Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity","volume":"9","author":"Ziyi Fu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.actbio.2024.09.033_bib0018","doi-asserted-by":"crossref","unstructured":"K.K. Michelle Ulrich, et al., Abstract 4892: MMAE drives immunomodulatory changes in a preclinical xenograft model that are distinct from other clinical-stage ADC payloads, Cancer Res. 83 (7_Supplement): 4892. (2023).","DOI":"10.1158\/1538-7445.AM2023-4892"},{"key":"10.1016\/j.actbio.2024.09.033_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pep.2020.105761","article-title":"Characterization of the Fc\u2013III\u20134C-based recombinant protein expression system by using carbonic anhydrase as the model protein","volume":"177","author":"Gong","year":"2021","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.actbio.2024.09.033_bib0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.actbio.2019.05.028","article-title":"Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma","volume":"92","author":"Wang","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2024.09.033_bib0021","article-title":"Self-amplifying nanotherapeutic drugs homing to tumors in a manner of chain reaction","volume":"33","author":"Wang","year":"2021"},{"issue":"4","key":"10.1016\/j.actbio.2024.09.033_bib0022","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1073\/pnas.0908801107","article-title":"Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis","volume":"107","author":"Stagg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"10","key":"10.1016\/j.actbio.2024.09.033_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.isci.2023.107778","article-title":"Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates","volume":"26","author":"Fu","year":"2023","journal-title":"iScience"},{"issue":"8","key":"10.1016\/j.actbio.2024.09.033_bib0024","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.actbio.2024.09.033_bib0025","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab vedotin-driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"18","key":"10.1016\/j.actbio.2024.09.033_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI172156","article-title":"Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response","volume":"133","author":"Chang","year":"2023","journal-title":"J. Clin. Investig."},{"issue":"9","key":"10.1016\/j.actbio.2024.09.033_bib0027","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S1470-2045(20)30234-5","article-title":"Turning up the heat on non-immunoreactive tumours: opportunities for clinical development","volume":"21","author":"Ochoa de Olza","year":"2020","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.actbio.2024.09.033_bib0028","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrc.2017.110","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"16","key":"10.1016\/j.actbio.2024.09.033_bib0029","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-10-1544","article-title":"CD73: a novel target for cancer immunotherapy","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.actbio.2024.09.033_bib0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.trecan.2016.01.003","article-title":"Anti-CD73 in cancer immunotherapy: awakening new opportunities","volume":"2","author":"Antonioli","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.actbio.2024.09.033_bib0031","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.breast.2020.03.005","article-title":"Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer","volume":"51","author":"Maranta","year":"2020","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.actbio.2024.09.033_bib0032","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.actbio.2024.09.033_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01322-3","article-title":"Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity","volume":"15","author":"Yan","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.actbio.2024.09.033_bib0034","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.actbio.2024.09.033_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers11101578","article-title":"The CD73\/Ado system-A new player in RT induced adverse late effects","volume":"11","author":"de Leve","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.actbio.2024.09.033_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.142843","article-title":"Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC","volume":"7","author":"Tu","year":"2022","journal-title":"JCI insight"},{"issue":"5","key":"10.1016\/j.actbio.2024.09.033_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2023-006842","article-title":"CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models","volume":"11","author":"Ye","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.actbio.2024.09.033_bib0038","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.actbio.2021.08.013","article-title":"Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1\/PD-L1 inhibitors than the parental drug","volume":"135","author":"Shen","year":"2021","journal-title":"Acta Biomater."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174270612400549X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174270612400549X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T22:39:31Z","timestamp":1762382371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S174270612400549X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":38,"alternative-id":["S174270612400549X"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2024.09.033","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual immunostimulatory CD73 antibody-polymeric cytotoxic drug complex for triple negative breast cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2024.09.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acta Materialia Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}